Surinabant Explained

Surinabant (SR147778) is a cannabinoid receptor type 1 antagonist developed by Sanofi-Aventis.[1] It is being investigated as a potential treatment for nicotine addiction, to assist smoking cessation. It may also be developed as an anorectic drug to assist with weight loss, however there are already several CB1 antagonists or inverse agonists on the market or under development for this application,[2] so surinabant is at present mainly being developed as an anti-smoking drug,[3] with possible application in the treatment of other addictive disorders such as alcoholism.[4] [5] Other potential applications such as treatment of ADHD have also been proposed.[6]

A dose ranging study was done for smoking cessation[7] in 2012; it did not improve success rate, but reduced weight gain. Inhibition of THC effects on heart rate was seen at 20 mg and 60 mg but not 5 mg.[8]

See also

Notes and References

  1. Rinaldi-Carmona M, Barth F, Congy C, Martinez S, Oustric D, Pério A, Poncelet M, Maruani J, Arnone M, Finance O, Soubrié P, Le Fur G . 6 . SR147778 [5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide], a new potent and selective antagonist of the CB1 cannabinoid receptor: biochemical and pharmacological characterization . The Journal of Pharmacology and Experimental Therapeutics . 310 . 3 . 905–14 . September 2004 . 15131245 . 10.1124/jpet.104.067884 . 25640461 .
  2. Doggrell SA . Will the new CB1 cannabinoid receptor antagonist SR-147778 have advantages over rimonabant? . Expert Opinion on Investigational Drugs . 14 . 3 . 339–42 . March 2005 . 15833065 . 10.1517/13543784.14.3.339 . 33937749 .
  3. Lamota L, Bermudez-Silva FJ, Marco EM, Llorente R, Gallego A, Rodríguez de Fonseca F, Viveros MP . Effects of adolescent nicotine and SR 147778 (Surinabant) administration on food intake, somatic growth and metabolic parameters in rats . Neuropharmacology . 54 . 1 . 194–205 . January 2008 . 17720206 . 10.1016/j.neuropharm.2007.07.004 . 22293050 .
  4. Gessa GL, Serra S, Vacca G, Carai MA, Colombo G . Suppressing effect of the cannabinoid CB1 receptor antagonist, SR147778, on alcohol intake and motivational properties of alcohol in alcohol-preferring sP rats . Alcohol and Alcoholism . 40 . 1 . 46–53 . 2005 . 15582988 . 10.1093/alcalc/agh114 . free .
  5. Lallemand F, De Witte P . SR147778, a CB1 cannabinoid receptor antagonist, suppresses ethanol preference in chronically alcoholized Wistar rats . Alcohol . 39 . 3 . 125–34 . July 2006 . 17127132 . 10.1016/j.alcohol.2006.08.001 .
  6. Louis C, Terranova JP, Decobert M, Bizot JC, Françon D, Alonso R, Cohen C, Griebel G . 2005 . Surinabant, a new CB1 receptor antagonist, displays efficacy in animal models of attention deficit/hyperactivity disorder . Behavioural Pharmacology . 16 . S42 . 10.1097/00008877-200509001-00133.
  7. Tonstad S, Aubin HJ . Efficacy of a dose range of surinabant, a cannabinoid receptor blocker, for smoking cessation: a randomized controlled clinical trial . Journal of Psychopharmacology . 26 . 7 . 1003–9 . July 2012 . 22219220 . 10.1177/0269881111431623 . 39145361 .
  8. Klumpers LE, Roy C, Ferron G, Turpault S, Poitiers F, Pinquier JL, van Hasselt JG, Zuurman L, Erwich FA, van Gerven JM . 6 . Surinabant, a selective cannabinoid receptor type 1 antagonist, inhibits Δ9-tetrahydrocannabinol-induced central nervous system and heart rate effects in humans . British Journal of Clinical Pharmacology . 76 . 1 . 65–77 . July 2013 . 23278647 . 3703229 . 10.1111/bcp.12071 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Surinabant".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.